Genascence Announces Initiation of Phase 1b Clinical Trial of GNSC-001 Gene Therapy for Knee Osteoarthritis (OA)

Phase 1b clinical trial in the U.S. is actively recruiting patients with OA at 10 sites Initial six-month data expected fourth quarter of 2024 PALO ALTO, Calif., Jan. 3, 2024 Genascence Corporation (“Genascence”), a clinical-stage biotechnology company revolutionizing the treatment of…

Click here to view original post

Advertisement — Advertise with Biotech Networks